• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Hepatitis B vaccination in preadolescents lowered the disease incidence rate in Catalonia

Bioengineer by Bioengineer
March 13, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An efficient program

IMAGE

Credit: UNIVERSITY OF BARCELONA

Introducing Hepatitis B vaccine in preadolescents meant a decline in the disease incidence rate by 52 % according to a study in which the University of Barcelona (UB) took part. The study analysed the efficiency and impact of the vaccination program set in Catalonia (Spain) twenty-one years ago. The results show that after introducing the program, the incidence rate in general population went from 2.5 per 100,000 people in 1991 to 1.2 per 100,000 people in 2014.

The study, published in the scientific journal Vaccine, counts on the participation of experts from the Research Group on Epidemiology, Prevention and Control of Communicable Diseases of the UB, the Public Health Agency of Catalonia and the Barcelona Public Health Agency, led by Professor Àngela Domínguez, from the Department of Medicine of the UB and the Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP, Institute of Health Carlos III).

Hepatitis B is a globally important viral disease due its morbidity, mortality and high chronicity in children. Chronicity increases the risk of cirrhosis and hepatocellular carcinoma, and patients with a chronic disease are permanent transmitters of the virus. In 1991, systematic vaccination for Hepatitis B was introduced in Catalonia in preadolescents. “So far, only risk groups were vaccinated, such as those working in the health sector or haemophiliac and haemodialytic patients. However, this type of vaccination was not enough to reduce the incidence”, note the researchers.

An efficient program

Researchers studied retrospectively vaccinated and non-vaccinated cohorts, chosen according to their year of birth, as well as cases of Hepatitis B between 2000 and 2014 that were registered by the Sub-Directorate General for Epidemiological Surveillance and Public Health Emergency Response of the Public Health Agency of Catalonia. During that period, they notified about 388 cases of Hepatitis B infection, 232 in the non-vaccinated cohort and 156 in the vaccinated cohort.

The incidence rate was 4.1 per 100,000 people per year in the non-vaccinated group and 0.03 per 100,000 people per year in the vaccinated group. Therefore, the efficiency of the program was 99.30 % and the associated benefit to estimate the prevented fraction was of 64.56 %. According to the researchers, these results show that “efficiency and impact of the vaccination program for Hepatitis B in preadolescents are high, benefiting the community”.

Vaccination in preadolescents was suspended in July 2014, when the first kids who had been vaccinated as children (vaccinated in 2002, aged one) reached preadolescence, so they did not need the vaccine again.

###

Media Contact
Rosa Martínez
[email protected]

Related Journal Article

http://dx.doi.org/10.1016/j.vaccine.2019.01.024

Tags: Disease in the Developing WorldHealth CareHealth ProfessionalsImmunology/Allergies/AsthmaMedicine/HealthPharmaceutical ChemistryPharmaceutical SciencePharmaceutical SciencesVaccinesVirology
Share12Tweet8Share2ShareShareShare2

Related Posts

Exploring Nurses’ Insights on Employee Assistance Programs

September 6, 2025

Sex Differences in Alcohol’s Impact on Brain Dopamine

September 6, 2025

Fecal Transplants: New Hope for Alzheimer’s Treatment

September 6, 2025

CheckMate 77T: Nivolumab Preserves Quality of Life and Mitigates Symptom Worsening in Resectable NSCLC

September 6, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    54 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring Nurses’ Insights on Employee Assistance Programs

Phase II Study Finds Iza-Bren Plus Osimertinib Achieves 100% Response Rate in EGFR-Mutated NSCLC

Novel Antibody-Drug Conjugate Demonstrates Promising Efficacy in EGFR-Mutated NSCLC Patients

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.